Studies open frequently. If interested in the latest information regarding our studies, please call Jen McGrain, MS RRT 410-328-1473.


You are being asked to take part in this research study because you have COPD. This study will compare a beta-blocker drug called metoprolol succinate with a placebo (an inactive substance). Metoprolol succinate is already approved by the U.S. Food and Drug Administration (FDA) to treat patients with cardiovascular disease usually after a myocardial infarction (MI). Metoprolol succinate is used to treat chest pain (angina), heart failure, and high blood pressure.

Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This lowers heart rate, blood pressure, and strain on the heart. This research study will test how well once daily metoprolol succinate works to reduce COPD flare-ups.

  • Principal Investigator: Robert M Reed, MD
  • Eligibility: Patients with COPD that have a history of smoking (current or past)
  • Reimbursements: You will be paid $75.00 for the screening visit and for the Day 336 visit. You will be paid $50.00 for each of the remaining 8 regularly scheduled clinic visits. If you complete the entire study, you will receive a total of $550.00.
  • Contact: Call 410-328-4155 or email


We are conducting the INSIGHT COPD study because symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. High BMI means that one’s body weight is higher than is ideal for one’s height. There are many medications for patients with COPD, but there is little mention of weight loss as a possible treatment in current research.

We are trying to find out if a lifestyle program that promotes modest weight loss and increased physical activity will improve COPD symptoms for those with a high BMI. We hope that the program will lead to weight loss and better exercise tolerance. We are also looking at the effects on shortness of breath, quality-of-life, and cardiovascular disease risk factors. 

  • Principal Investigator: Robert M Reed, MD
  • Eligibility: Patients with COPD that are age 40 or older and are overweight
  • Reimbursements: $40 at the baseline visit. $20 at the 12 Month visit. $40 at the 18 Month visit. If you complete all visits and are in the Intervention group, you will receive an additional $50. If you complete all visits and are in the Control Group, you will receive a Fitbit.
  • Contact: Call 410-328-4155 or email

Pulmonary Fibrosis Foundation Registry

This study has two overall goals or arms:

The first is to create and maintain a Pulmonary Fibrosis Foundation Patient Registry (hereafter referred to as the National Registry) of patients with interstitial lung disease and/or pulmonary fibrosis. Interstitial lung diseases (ILD) are a group of diseases characterized by progressive fibrosis (scarring) of the lung tissue leading to difficulty breathing.

You are being asked to participate in this study because your physician has determined that you have ILD and/or pulmonary fibrosis. The data which we collect and incorporate into this National Registry will be analyzed with the goals of improving quality of life and improving outcomes of patients with ILD and/or pulmonary fibrosis. This is an observational National Registry which means you will not receive any investigational treatments or investigational drugs. Your disease management and treatment decisions will be determined by you and your health care professional.

The second goal of this study is to create a Pulmonary Fibrosis Foundation Central Biorepository of samples from patients with ILD and/or pulmonary fibrosis. The Central Biorepository will contain biological samples which will be linked to medical information from enrolled patients. We hope to be able to answer questions about ILD and/or pulmonary fibrosis by analyzing these blood samples for specific genes and other markers of disease.

Researchers at institutions across the country will be able to request samples from the Central Biorepository to hopefully assist them in their own research studies into ILD and/or pulmonary fibrosis.